In pursuit of drugs for American trypanosomiasis: evaluation of some "standards" in a mouse model

Proc Soc Exp Biol Med. 1997 Dec;216(3):424-8. doi: 10.3181/00379727-216-44192.

Abstract

Forty-nine "standard" compounds known to be useful in the treatment of other diseases were tested for their suppressive activity against the trypomastigotes of Trypanosoma cruzi-infected mice. The most active was the antidepressant protriptyline, which was almost three times as effective as the reference drug, nifurtimox. A major value of the present data is to demonstrate the refractoriness of the T. cruzi parasite against many of the drug standards that have known biological activity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antiprotozoal Agents / therapeutic use*
  • Chagas Disease / drug therapy*
  • Chagas Disease / parasitology
  • Disease Models, Animal
  • Female
  • Imipramine / chemistry
  • Imipramine / therapeutic use
  • Ketoconazole / therapeutic use
  • Mice
  • Mice, Inbred Strains
  • Nifurtimox / therapeutic use
  • Nigericin / therapeutic use
  • Niridazole / therapeutic use
  • Protriptyline / chemistry
  • Protriptyline / therapeutic use
  • Trypanosoma cruzi / drug effects*
  • Trypanosoma cruzi / growth & development

Substances

  • Antiprotozoal Agents
  • Protriptyline
  • Nifurtimox
  • Niridazole
  • Imipramine
  • Ketoconazole
  • Nigericin